A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.

Published online

Journal Article

INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzheimer's disease (AD) subjects from healthy elderly control (HC) subjects. METHODS: A CSF tau/Aβ42 cutoff criteria was chosen, which distinguished the groups and maximized concordance with amyloid PET. Performance was assessed using an independent validation cohort. RESULTS: A tau/Aβ42 = 0.215 cutoff provided 94.8% sensitivity and 77.7% specificity. Concordance with PET visual reads was estimated at 86.9% in a ∼50% PET positive population. In the validation cohort, the cutoff demonstrated 78.4% sensitivity and 84.9% specificity to distinguish the AD and HC populations. DISCUSSION: A tau/Aβ42 cutoff with acceptable sensitivity and specificity distinguished HC from mild-to-moderate AD subjects and maximized concordance to brain amyloidosis. The defined cutoff demonstrated that CSF analysis may be useful as a surrogate to imaging assessment of AD pathology.

Full Text

Duke Authors

Cited Authors

  • Mo, Y; Stromswold, J; Wilson, K; Holder, D; Sur, C; Laterza, O; Savage, MJ; Struyk, A; Scheltens, P; Teunissen, CE; Burke, J; Macaulay, SL; Bråthen, G; Sando, SB; White, LR; Weiss, C; Cowes, A; Bush, MM; DeSilva, G; Darby, DG; Rainey-Smith, SR; Surls, J; Sagini, E; Tanen, M; Altman, A; Luthman, J; Egan, MF

Published Date

  • 2017

Published In

Volume / Issue

  • 6 /

Start / End Page

  • 201 - 209

PubMed ID

  • 28349119

Pubmed Central ID

  • 28349119

International Standard Serial Number (ISSN)

  • 2352-8729

Digital Object Identifier (DOI)

  • 10.1016/j.dadm.2017.02.004


  • eng

Conference Location

  • Netherlands